IsomAb announces Development Candidate nomination with Pfizer for Peripheral Arterial Disease
IsomAb Ltd, a UK-based biotechnology company developing isoform-specific disease modifying antibody treatments for serious and life-threatening diseases, on Wednesday announced the nomination of a Development Candidate for peripheral arterial disease (PAD …